🔎 Trials Near Me

Pradžia › Limfoma › Tennessee

Limfoma klinikiniai tyrimai Tennessee

15 tyrimai dėl Limfoma ieško dalyvių vietose Tennessee.

Miestai Tennessee

Oficialus tyrimo tekstas (anglų kalba)

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

  • Sarah Cannon Research Institute Oncology Partners, Nashville
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07015242

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

  • St. Jude Children's Research Hospital, Memphis
Renkami dalyviai1/2 fazė
Iki 25 metų · Visoms lytims · Atnaujinta 2026-09-25 · NCT04094610

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • SCRI Oncology Partners, Nashville
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT07221500

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Saint Jude Children's Research Hospital, Memphis
Renkami dalyviai1/2 fazė
12 Months – 21 Years · Visoms lytims · Atnaujinta 2026-09-11 · NCT04870944

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

  • SCRI Oncology Partners, Nashville
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-04 · NCT07082803

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

  • Sarah Cannon Research Institute, Nashville
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT07284433

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Vanderbilt University Medical Center, Nashville
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT05826535

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • TriStar BMT, Nashville
Renkami dalyviai1/2 fazė
Amžius nuo 13 iki 90 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • SCRI Oncology Partners, Nashville
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-04 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • SCRI Oncology Partners, Nashville
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-13 · NCT04792489

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • Baptist Clinical Research Institute, Memphis
Renkami dalyviai1/2 fazė
Amžius nuo 12 iki 95 · Visoms lytims · Atnaujinta 2026-04-15 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • Tennessee Oncology, Nashville
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-20 · NCT04830137

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

  • St. Jude Children's Research Hospital, Memphis
Renkami dalyviai1 fazė
Iki 21 metų · Visoms lytims · Atnaujinta 2026-01-23 · NCT06326463

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Baptist (BHMCC), Memphis
  • Vanderbilt-Ingram Cancer Center, Nashville
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius 40 ir vyresni · Visoms lytims · Atnaujinta 2026-01-20 · NCT05366881

HPC Offered for PRESERVE Expansion

  • Tristar Centennial Medical Center, Nashville
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 12 iki 80 · Visoms lytims · Atnaujinta 2025-08-28 · NCT07145411

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.